EP0186071A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Transdermal system for timolol
Assignee: Merck and Co Inc
•
Filing: 1985-12-13
•
Granted: —
•
Expires: 2005-12-13
Abstract
Abstract A system for administering timolol for an extended period is described. The system comprises a backing member (11) substantially impermeable to the drug, a drug reservoir member (12), consisting essentially of timolol as the drug and carrier therefor, and a rate controlling member (15). By the system, transdermal application of timolol may be accomplished with substantially no irritation to the skin.
Inventors
- 👤 Joseph V. Bondi
- 👤 Alice E. Loper
- 👤 Edward M. Cohen
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-27 22:36
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K31/00; A61K31/33; A61K31/395; A61K31/535
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
80 words
A process for preparing a transdermal delivery system suitable for administering timolol for an extended period which comprises combining (a) a backing member, said backing member being substantially impermeable to the drug, (b) a drug reservoir member, consisting essentially of timolol as the drug and carrier therefor, and (c) a rate controlling member, said member controlling the flow of timolol from the reservoir to the skin surface at a rate no greater than 20 micrograms per square centimeter per hour.
Claim 2
Dependent Claim
80 words
A process for preparing a transdermal delivery system suitable for administering timolol for an extended period which comprises combining (a) a backing member, said backing member being substantially impermeable to the drug, (b) a drug reservoir member, consisting essentially of timolol as the drug and carrier therefor, and (c) a rate controlling member, said member controlling the flow of timolol from the reservoir to the skin surface at a rate no greater than 20 micrograms per square centimeter per hour.
Claim 3
Dependent Claim
19 words
A process according to Claim 1 wherein the carrier for the drug in the reservoir is gelled mineral oil.
Claim 4
Dependent Claim
29 words
A process accoring to Claim 1 or 2 wherein the rate controlling member is a membrane and said membrane is of microporous polypropylene, ethylene vinyl acetate, silicone or polyurethane.
Claim 5
Dependent Claim
13 words
A process according to Claim 3 wherein the membrane is of laminated multilayers.
Claim 6
Dependent Claim
94 words
A process for preparing a transdermal patch suitable for administering timolol for an extended period which comprises combining (a) a backing member of a material substantially impermeable to timolol; (b) a drug reservoir member adjacent to and coextensive with one face of said backing member, said drug reservoir member consisting essentially of timolol and a carrier therefor; (c) a rate controlling member superposed on the drug reservoir member, said rate controlling member comprising at least one layer of a microporous membrane; and (d) an adhesive layer for affixing to the skin of a patient.
Claim 7
Dependent Claim
94 words
A process for preparing a transdermal patch suitable for administering timolol for an extended period which comprises combining (a) a backing member of a material substantially impermeable to timolol; (b) a drug reservoir member adjacent to and coextensive with one face of said backing member, said drug reservoir member consisting essentially of timolol and a carrier therefor; (c) a rate controlling member superposed on the drug reservoir member, said rate controlling member comprising at least one layer of a microporous membrane; and (d) an adhesive layer for affixing to the skin of a patient.
Claim 8
Dependent Claim
35 words
A process according to Claim 5 wherein the carrier in the reservoir is gelled mineral oil and the rate controlling member is (a) a film of polyisobutylene and mineral oil or (b) microporous polypropylene membrane.
Claim 9
Dependent Claim
40 words
A process according to Claim 5 wherein the carrier in the drug reservoir member is gelled mineral oil and the rate controlling member is a combination of (a) a film of polyisobutylene and mineral oil and (b) microporous polypropylene membrane.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.